COLLNasdaqPharmaceutical PreparationsFiscal year ends December 31
COLLEGIUM PHARMACEUTICAL, INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$23.01−0.18 (-0.78%)
Close on Oct 19, 2026
- Market cap
- $746.92M
- P/E (TTM)
- 18.6
- Dividend yield
- –
COLLEGIUM PHARMACEUTICAL, INC revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Belbuca | $227.71M | $222.64M | $221.65M | $217.72M | $212.67M | $212.26M | $211.27M | $205.36M | $197.61M | $188.55M | $182.10M | $174.84M | 28.2% | +7.1% |
| Jornay PM | $172.64M | $159.21M | $148.86M | $132.25M | $98.40M | – | $37.24M | – | – | – | – | – | 21.4% | +75.4% |
| Xtampza ER | – | – | – | $202.18M | $201.19M | $193.16M | $191.33M | $188.34M | $178.64M | $175.32M | $177.37M | $164.15M | – | – |
| Nucynta IR | – | – | – | $110.12M | $103.50M | $102.20M | $100.74M | $103.71M | $103.26M | $106.21M | $108.15M | $109.86M | – | – |
| Nucynta ER | – | – | – | $79.98M | $76.94M | $76.27M | $75.77M | $77.94M | $80.80M | $80.70M | $82.65M | $81.89M | – | – |
| Symproic | – | – | – | $14.82M | $14.31M | $14.62M | $15.10M | $15.94M | $16.34M | $16.15M | $16.50M | $15.94M | – | – |
By region
From the segment and revenue-disaggregation notes of Collegium Pharmaceutical's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.